Fenpropathrin


CAS No. : 39515-41-8

39515-41-8
Price and Availability of CAS No. : 39515-41-8
Size Price Stock
50mg $50 In-stock
100mg $80 In-stock
200 mg Get quote
500 mg Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-123178
M.Wt: 349.42
Formula: C22H23NO3
Purity: >98 %
Solubility: DMSO : 100 mg/mL (ultrasonic)
Introduction of 39515-41-8 :

Fenpropathrin is a synthetic pyrethroid insecticide in agriculture. Fenpropathrin may induces parkinsonian symptoms progressively[1].
In Vivo:Note:
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

Fenpropathrin can be used in animal modeling to create Parkinson's syndrome models. Fenpropathrin is lipophilic, allowing it to cross the blood-brain barrier, and it is characterized by rapid metabolic clearance in mammals[1].

1. Induction of Parkinson's syndrome[1]
Background
Fenpropathrin can cause an increase in dopamine transporter (DAT) levels and a decrease in vesicular monoamine transporter 2 (VMAT2) levels, which raises the cytoplasmic concentration of dopamine, worsening the damage to dopamine neurons and leading to Parkinson's syndrome.
Specific Modeling Methods
Rat: Sprague-Dawley (SD) • male
Administration: 15 mg/kg, i.p. • 1 μL of 6 μg/μL Fenpropathrin solution, stereotaxical infusion • once daily for 60 days
Note
(1) When injected into the abdominal cavity, Fenpropathrin is dissolved in corn oil; during the ST infusion, Fenpropathrin is dissolved in DMSO, with an injection volume of 1 μL.
(2) Half of the rats did not receive any treatment within 60 days after the last injection of Fenpropathrin, while the other half of the rats were euthanized 24 hours after the last Fenpropathrin treatment.
(3) For ST infusion, Fenpropathrin solution was injected into the right ventral tegmental area and substantia nigra pars compacta (SNc) at a flow rate of 0.2 μ L/min. After injection, the needle was left in place for 5 minutes to allow the drug to fully diffuse, and then the needle was slowly removed.
(4) Measure the levels of dopamine, DOPAC, and HVA in the striatum using HPLC.
(5) Slice the brain tissue into 15 μm thick sections using a low-temperature cryostat to analyze the immunoreactivity of DAT and VMAT2.
Modeling Indicators
Molecular changes: Tyrosine hydroxylase (TH) and vesicular monoamine transporter 2 (VMAT2) show reduced immune reactivity, while dopamine transporter (DAT) immune reactivity increases; the levels of dopamine, DOPCA, and HVA in the body decrease.
Behavioral observation: After 4 weeks of treatment, there was a decrease in movement activity, less climbing, reduced escape behavior, and slower movement.

Your information is safe with us.

Our product is for R&D purpose only.